Pathstone Holdings
COGT icon

Pathstone Holdings’s Cogent Biosciences COGT Stock Holding History

Pathstone Holdings’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$942K Buy
+24,349
New +$852K ﹤0.01% 1533
2024
Q1 		– Sell
-17,599
Closed -$103K – 2308
2023
Q4 		$103K Buy
+17,599
New +$135K ﹤0.01% 2145

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pathstone Holdings's COGT Position: Q2 2026 in Review

Pathstone Holdings opened a new position in Cogent Biosciences (COGT) in Q2 2026: 24,349 shares worth $942K. The stake represents ﹤0.01% of the portfolio and ranks #1533 among its holdings. This is a return to the name: Pathstone Holdings previously reported a position in COGT as recently as Q4 2023.

Pathstone Holdings first reported a position in COGT in Q4 2023 and has held it in 2 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Pathstone Holdings held 24,349 shares of Cogent Biosciences worth $942K as of Q2 2026.
  • Cogent Biosciences was a new Pathstone Holdings position in Q2 2026.
  • Cogent Biosciences made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1533 holding.
  • Pathstone Holdings first reported a position in Cogent Biosciences in Q4 2023 and has held it in 2 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.